Manas and Microsoft have established a joint partnership to combine the tech leader's word-class AI capabilities and infrastructure with the unparalleled drug design and development expertise of Manas.
Disrupting drug discovery with AI and compute power.
Manas AI generates bespoke chemical libraries and utilizes advanced AI filters to identify high-potential therapeutic candidates with paradigm-shifting speed and accuracy.
Manas AI is built on top of Azure cloud, enabling molecular docking speeds 100x faster than traditional systems.
The company’s ambitious AI-driven initiative aims to map the fundamental "rules" of drug binding, further accelerating the discovery of novel chemical entities.
With an initial focus on oncology, Manas AI is developing treatments for aggressive cancers such as triple-negative breast cancer, prostate cancer, and lymphoma. Eventually, the company also intends to target important other global diseases.
